Recent Updates
Recently added Catalysts
ETON Positive Sentiment Score: 70/100

Eton Pharmaceuticals to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023

Monday, October 30, 2023 2 min read
Key Takeaway: Eton Pharmaceuticals, Inc. has announced the timing for its third quarter 2023 financial results, set to be released on November 9, 2023. The company will host a conference call and live audio webcast to discuss these results, allowing investor questions to be addressed both live and via email. Eton focuses on developing and commercializing products for rare diseases, with several FDA-approved treatments and additional candidates in late-stage development.

Market Sentiment Analysis

POSITIVE FACTORS

  • Eton Pharmaceuticals is committed to addressing unmet needs in rare diseases.
  • The company has four FDA-approved products for rare diseases.
  • Management will engage directly with investors during the conference call.

Full Press Release Details

DEER PARK, Ill., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing, acquiring, and commercializing products to address unmet needs in patients suffering from rare diseases, today announced that it will report third quarter 2023 financial results on Thursday, November 9, 2023. Management will host a conference call and live audio webcast to discuss these results at 4:30 p.m. ET (3:30 p.m. CT).
Register* (Audio Only)         Click here
In addition to taking live questions from participants on the conference call, management will be answering emailed questions from investors. Investors can email questions to: investorrelations@etonpharma.com.
The live webcast can be accessed on the Investors section of Eton’s website at https://ir.etonpharma.com/. An archived webcast will be available on Eton’s website approximately two hours after the completion of the event and for 30 days thereafter.
* Conference call participants should register to obtain their dial-in and passcode details. Please be sure to register using a valid email address.
About Eton Pharmaceuticals
Eton is an innovative pharmaceutical company focused on developing, acquiring, and commercializing products to address unmet needs in patients suffering from rare diseases. The Company currently has four FDA-approved rare disease products, ALKINDI SPRINKLE® for the treatment of pediatric adrenocortical insufficiency, Carglumic Acid for the treatment of hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency, Betaine Anhydrous for the treatment of homocystinuria, and Nitisinone for the treatment of hereditary tyrosinemia type 1. The Company has four additional product candidates in late-stage development: ET-400 for the treatment of adrenocortical insufficiency, ET-600 for the treatment of diabetes insipidus, ZENEO® hydrocortisone autoinjector for the treatment of adrenal crisis, and dehydrated alcohol injection for the treatment of methanol poisoning. For more information, please visit our website at www.etonpharma.com.
Lisa M. Wilson, In-Site Communications, Inc.
E: lwilson@insitecony.com
Source: Eton Pharmaceuticals

Frequently Asked Questions

When will Eton Pharmaceuticals report Q3 2023 results?

Eton Pharmaceuticals will report Q3 2023 financial results on November 9, 2023.

How can I access the Q3 financial results webcast?

The live webcast can be accessed on Eton's Investors section of their website.

Can I ask questions during the conference call?

Yes, participants can ask live questions or email questions to investorrelations@etonpharma.com.

What products does Eton Pharmaceuticals offer?

Eton has four FDA-approved products for rare diseases, including ALKINDI SPRINKLE®.

What candidates are in Eton's late-stage development?

Eton has four candidates in late-stage development, including ET-400 for adrenocortical insufficiency.

Tags: ETON Viatris Investor Conferences Healthcare Eton Pharmaceuticals Q3 2023 financial results FDA-approved products rare diseases
Last updated: Oct 30, 2023